Biomarkers in breast cancer

Central European Journal of Medicine

Volumn 1, Issue 4, 2006, Pages 330-347

  Laguens, Graciela ^a   Coronato, Silvia ^a   Di Girolamo, Wanda ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Breast cancer; Tumour markers

Indexed keywords

EID: 33845326766     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-006-0032-9     Document Type: Review

References (67)

1. K. Dhingra and G.N. Hortobagyi: "Critical evaluation of prognostic factors", Sem. Oncol., Vol. 23, (1996), pp. 436-445.
2. J. Sjostrom, C. Blomqvist, P. Heikkila, K.V. Bogulawski, A. Raiseanen-Sokolowski, N.O. Bengtsson, I. Mjaaland, P. Malmstron, B. Ostenstadt, J. Berg, E. Wist, V. Valvere and E. Saksela: "Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer", Clin. Cancer Res., Vol. 6(8), (2000), pp. 3103-3110.
3. K.L. Cheung, C.R. Graves and J.F. Robertson: "Tumour marker measurements in the diagnosis and monitoring of breast cancer", Cancer Treat. Res., Vol. 26, (2000), pp. 91-102.
4. V. Stearns, H. Yamauchi and D.F. Hayes: "Circulating tumour markers in breast cancer: accepted utilities a novel prospect", Breast Cancer Res. Treat., Vol. 52, (1998), pp. 239-259.
5. J. Martinez-Trufero, A.R. de Lobera, J. Lao, T. Puertolas, A. Artal-Cortes, M. Zorrilla, V. Alonso, R. Pazo, M.I. Valero, M.J. Rios-Mitchell, V. Calderero, A. Herrero and A. Anton: "Serum markers and prognosis in locally advanced breast cancer", Tumori, Vol. 91, (2005), pp. 522-530.
6. D. Haidopoulos, M.M. Konstadoulakis, P.T. Antonakis, D.G. Alexiou, A.M. Manouras, S.M. Katsaragakis and G.F. Androulakis: "Circulating anti-CEA anti-bodies in the sera of patients with breast cancer", Eur. J. Surg. Oncol., Vol. 26, (2000), pp. 742-746.
7. D. Allred, J. Harvey, M. Berardo and G. Clark: "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod. Pathol., Vol. 11, (1998), pp. 155-168.
8. P.L. Fitzgibbons, D.L. Page, D. Weaver, A.D. Thor, B.C. Allred, G.M., Clark, S.G. Ruby, F.O'Malley, J.F. Simpson, J.L. Conolly, D.F. Hayes, S.B. Edge, A.Lichter and S.J. Schnitt: "Prognostic factors in breast cancer", Arch. Pathol. Lab. Med., Vol. 124, (2000), pp. 966-978.
9. R. Heimann and S. Hellman: "Individual characterisation of the metastatic capacity of human breast carcinoma", Eur. J. Cancer, Vol. 36, (2000), pp. 1631-1639.
10. E.L. Dupont, M.A. Kuhn, C. McCann, C. Salud, J.L. Spanton and C.E. Cox: "The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy", Am. J. Surg., Vol. 180, (2000), pp. 274-277.
11. P.J. Borgstein, S. Meijer, R.J. Pijpers and P.J. van Diest: "Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method", Ann. Surg., Vol. 232, (2000), pp. 81-89.
12. H.J.G. Bloom, and W.W. Richardson: "Histological grading and prognosis in breast cancer: A study of 1.709 cases of which 359 have been followed for 15 years", Br. J. Cancer, Vol. 2, (1957), pp. 353-377.
13. B. Helpap: "Nucleolar grading of breast cancer", Virchows Archiv. A Pathol. Anat. Vol. 415 (1989), pp. 501-508.
14. I.O. Elis, C.W. Elston and R.W. Blamey: "The Nottingham prognosis index (NPI) a combination of multiple prognostic factors derived from the Nottingham Tenovus primary cancer study", Mod. Pathol., Vol. 4, (1991), p. 11.
15. E.R. Fisher and B. Fisher: "Lobular carcinoma of the breast: an overview", Ann. Surg., Vol. 185, (1977), pp. 377-385.
16. X. Cui, R. Schiff, G. Arpino, C.K. Osborne and A.V. Lee: "Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy", J. Clin. Oncol., Vol. 23, (2005), pp. 7721-7735.
17. B. Jasani, A Douglas-Jones, A. Rhodes, S. Wozniak, P.J. Barrett-Lee, J. Gee and R. Nicholson: "Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections", Methods Mol. Med., Vol. 120, (2006), pp. 127-146.
18. J.D.Yager and N.E. Davidson: "Estrogen carcinogenesis in breast cancer", N. Engl. J. Med., Vol. 354, (2006), pp. 270-282.
19. X.Chen, C. Danes, M. Lowe, T.W. Herliczek and K. Keyomarsi: "Activation of the Estrogen-Signaling Pathway by p21 (WAF1/CIP1) in Estrogen Receptor-negative breast cancer cells", J. Natl. Cancer Inst., Vol. 92, (2000), pp. 1403-1413.
20. R. Schiff, S.A. Massarweh, J. Shou, L. Bharwani, G. Arpino, M. Rimawi and C.K. Osborne: "Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators", Cancer Chemother. Pharmacol., Vol. 56, (2005), pp. 10-20.
21. N. Normanno, M. Di Maio, E. Di Maio, A. De Luca, A. de Matteis, A. Giordano and F. Perrone: "Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer", Endocr. Relat. Cancer, Vol. 12, (2005), pp. 721-747.
22. A. Starr, K. Bloom, D. Oleske and M. Cobleigh: "Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in determining HER-2/neu status in breast cancer patients", Proc. Am. Soc. Clin. Oncol., 2000 ASCO Annual Meeting, abstract No. 2610.
23. A.A. Sahin: "Biologic and clinical significance of HER-2/neu (c-erbB-2) in breast cancer", Adv. Anat. Pathol., Vol. 7, (2000), pp. 158-166.
24. F.J. Esteva, C.D. Cheli, H. Fritsche, M.D. Slamon, R.P. Thiel, D. Luftner and G. Farooq: "Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies", Breast Cancer Res., Vol. 7, (2005), pp. 436-443.
25. L.D. Miller, J. Smeds, J. George, V.B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E.T. Liu and J. Bergh: "An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival", Proc. Natl. Acad. Sci. USA., Vol. 102, (2005), pp. 13550-13555.
26. S.J. Schnitt: "Traditional and Newer Pathologic Factors", J. Nat. Cancer Ins. Mon., Vol. 30, (2001), pp. 22-26.
27. H. Takei, Y. Iino, J. Horiguchi, M. Maemura, H. Nagaoka, Y. Koibuchi, T. Yokoe, T. Oyama and Y. Moreshita : "Highest microvessel count as a long-term prognostic factor in Japanase breast cancer patients", Cancer Lett., Vol. 156, (2000), pp. 109-116.
28. G. Gasparini: "Clinical significance of determination of surrogate markers of angiogenesis in breast cancer", Crit. Rev. Oncol. Hematol., Vol. 37, (2001), pp. 97-114
29. J. Boyle: "Histological measurement of tumour angiogenesis", Eur. J. Cancer, Vol. 39, (2003), pp. 859-860.
30. D. Cruz, C. Valenti, A. Dias, M. Seixas and F. Schmitt: "Microvessel density counting in breast cancer. Slides vs. digital images", Anal. Quant. Cytol. Histo., Vol. 23, (2001), pp. 15-20.
31. G. Gasparini: "Prognostic value of vascular endothelial growth factor in breast cancer", Oncologist, Vol. 5, (2000), pp. 37-44,
32. G. Callagy, E. Dimitriadis, J. Harmey, D. Bouchier-Hayes, M. Leader and E. Kay: "Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor". Appl. Immunohistochem. Molecul. Morphol., Vol. 8, (2000), pp. 104-109.
33. N. Boudreau and C. Myers: "Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment", Breast Cancer Res., Vol. 5, (2003), pp. 140-146.
34. P.H. Tan, B.H. Bay, G.Yip, S. Selvarrajan, P. Tan, J. Wu, C.H. Lee and K. B. Lee: "Immunohistochemical detection of Ki 67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death", Mod. Pathol., Vol. 18, (2005), pp. 374-381.
35. S.A. Aziz, S. Pervez, S.M. Khan, N. Kayani and M. I. Nasir: "Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast", J. Coll. Physicians Surg. Pak., Vol. 15, (2005), pp. 225-229.
36. A. Sidoni, G.A. Cavalieri, G. D'Amico, G. Brachelente and E. Bucchiarelli: "Biopathological significance of single cell DNA aneuploidy measured by static cytometry in breast cancer", The Breast, Vol. 10, (2001), pp. 325-329.
37. J. Adams, P.J. Carder, S. Downey, M.A. Forbes, K. MacLennan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J.J. Walker, F. Cairnduff, P.J. Selby, T.J. Perren, M. Lansdown and R.E. Banks: "Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen", Cancer Res., Vol. 60, (2000), pp. 2898-2905.
38. R.S. Rampaul, S.E. Pinder, R.I. Nicholson, W.J. Gullick, J.F. Robertson and I.O. Ellis: "Clinical value of epidermal growth factor receptor expression in primary breast cancer", Adv. Anat. Pathol., Vol. 12, (2005), pp. 271-273.
39. H.W. Lo, S.C. Hsu and M.C. Hung: "EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization", Breast Cancer Res. Treat., Vol. 28 (2005), pp. 1-8.
40. H. Rochefort, M. Garcia, M. Glondu, V. Laurent, E. Liaudet, J. Rey and P. Roger: "Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview", Clin. Chim. Acta, Vol. 291, (2000), pp. 157-170.
41. A.M. Billgren, L.E. Rutqvist, H. Johansson, T. Hagerstrom and L. Skoog: "The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen", Eur. J. Cancer, Vol. 36, (2000), pp. 1374-1380.
42. R. Gonzalez Cámpora, M. Galera Ruiz, F. Vázquez Ramírez, J.J. Rios Martín, J.M. Fernández Santos, M.M. Martos and A. Gómez Pascual: "Apoptosis in breast carcinoma", Pathol. Res. Pract., Vol. 196, (2000), pp. 167-174.
43. B. Agrawal, M. Krantz, M. Reddish and B. Longenecker: "Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2". Nat. Med., Vol. 4, (1998), pp. 43-49.
44. E.A. Rakha, R.W. Boyce, D. Abd El-Rehim, T. Kurien, A.R. Green, E.C. Paish, J.F. Robertson and I.O. Ellis: "Expression of mucins (MUC1, MUC5AC and MUC6) and their prognostic significance in human breast cancer", Mod. Pathol., Vol. 8, (2005), pp. 1295-1304.
45. N. Berois N, M. Varangot and C. Sonora: "Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5b mRNA", Int. J. Cancer, Vol. 1.03, (2003), pp. 550-555.
46. K. Yoshikawa, T. Ogawa, R. Baer, H.Hemmi, K. Honda, A. Yamauchi, T. Inamoto, K. Ko, S. Yazumi, H. Motoda, H. Kodama, S. Noguchi, A.F. Gazdar, Y. Yamaoka and R. Takahashi: "Abnormal expression of BCRA1 and BCRA2- interactive DNA-repair proteins in breast carcinomas", Int. J. Cancer, Vol. 88, (2000), pp. 28-36.
47. J. Rogozinska-Szczepka, B. Utracka-Hutka, E. Grzybowska, B. Maka, E. Nowicka, A. Smok-Ragankiewicz, H. Zientek, J. Steffen and A. Wojciechowska-Lacka: "BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients", Ann. Oncol., Vol. 1.5, (2004), pp. 1373-1376.
48. P.K. Auvinen, P.K. Lipponen, V.V. Kataja, R.T Johansson and K. J. Syrjanen: "Prognostic significance of TGFα expression in breast cancer", Acta Oncologica, Vol. 35, (1996), pp. 995-998.
49. M. J. Duffy: "Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies", Clin. Chem., Vol. 48, (2002), pp. 1194-1197.
50. P. Chrzan, J. Skolowski, A. Karmolinski and T. Pawelczyk: "Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue", Clin. Biochem., Vol. 34, (2001), pp. 557-562.
51. V. Masciullo, K. Khalili and A.Giordano: "The Rb family of cell cycle regulatory factors: clinical implications" (Review), Int. J. Oncol., Vol. 17, (2000), pp. 897-902.
52. S. Zhang, S.C. Liu, L.F. Al-Saleem, D. Holloran, J. Babb, X. Quo and A.J. Klein-Szanto: "E2F-1: a proliferative marker of breast neoplasia", Cancer Epidemiol. Biomarkers Prev., Vol. 9, (2000), pp. 395-401.
53. S. Coronato, V. Di Girolamo, M. Salas, O. Spinelli and G. Laguens: "Biología de las proteínas del shock térmico", Medicina, Buenos Aires, Vol 59, (1999), pp. 477-486.
54. D.H. Ciocca and S.K. Calderwood: "Heat shock proteins in cancer: diagnostic, prognostic, predictive and treatment implications", Cell Stress Chaperons, Vol. 10, (2005), pp. 86-103.
55. S.K. Calderwood, M..A, Khaleque, D.B. Sawyer and D.R. Ciocca: "Heat shock proteins in cancer: chaperones of tumorigenesis", Trends Biochem. Sci., Vol. 31, (2006), pp. 164-1.72.
56. G.E. Laguens, S. Coronato, O. Spinelli, R.P. Laguens and V. Di Girolamo: "Can breast cancer Hsp27 (Heat Shock Protein 27000) expression influence axillary lymph node status?", The Breast, Vol. 10, (2001), pp. 179-181.
57. A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, D. Reppa and V. Georgoulias: "Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance", J. Clin. Oncol., Vol. 20, (2002), pp. 3404-3412.
58. N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, Ch. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, E. Lianidou and V. Georgoulias: "Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer", Ann. Oncol., Vol. 14, (2003), pp. 849-855.
59. G. Spizzo, G. Gastl, D. Wolf, E. Gunsilius, M. Steurer, D. Fong, A. Amberger, R. Margreiter and P. Obrist: "Correlation of Cox-2 and Ep-CAM, overexpression in human invasive breast cancer and its impact on survival", Br. J. Cancer, Vol. 88, (2003), pp. 574-578.
60. G. Spizzo, P. Obrist, C. Ensinger, I. Theurl, M. Dunser, A. Ramoni, E. Gunsilius, G. Eibl, G. Mikuz and G. Gastl: "Prognostic significance of EP-CAM. and Her-2/neu overexpression in invasive breast cancer" Int. J. Cancer, Vol. 98, (2002), pp. 883-888.
61. J.A. King, S. Ofori-Acquah and T. Stevens: "Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator", Breast Cancer Res., Vol. 6, (2004), pp. 478-487.
62. M.J. Duffy: "Predictive markers in breast and other cancers: a review", Clin. Chem., Vol. 51, (2005), pp. 494-503.
63. I. Benoy, R. Salgado, H.Elst, P. Van Dam, J. Weyler, E. Van Marck, S. Scharpe, P.B. Vermeulen and L.Y. Dirix: "Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases in patients with clinically non-metastatic breast cancer", Breast Cancer Res., Vol. 7, (2005), pp. 210-219.
64. A. Lindblom and A. Liljegren: "Tumour markers in malignancies" B.M.J., Vol. 320, (2000), pp. 424-427.
65. R. Molina, V. Barak, A. van Dalen, M.J. Duffy, R. Einarsson, M. Gion, H. Goike, R. Lamertz, M. Nap, G. Soletormos and P. Stieber: "Tumor markers in breast cancer-European Group on tumor markers recommendations", Tumour Biol., Vol. 26, (2005), pp. 281-293.
66. A. Urruticoechea, I.E. Smith and M. Dowsett: "Proliferation marker Ki-67 in early breast cancer", J. Clin. Oncol., Vol. 23, (2005), pp. 7212-7220.
67. G. Gasparini, R. Longo, M. Toi and N. Ferrara: "Angiogenic inhibitors: a new therapeutic strategy in oncology", Nat. Clin. Pract. Oncol., Vol. 2, (2005), pp. 562-577.